Rabbit monoclonal antibodies are relatively new in the immunohistochemistry (IHC) field. The majority of rabbit monoclonal antibodies are developed using a patented and proprietary rabbit hybridoma technology—the RabMAb® hybridoma technology. RabMAb primary antibodies offer greater advantages over classic mouse monoclonal antibodies, providing higher binding affinity, more diversified antigenic epitope recognition and a highly stable IgG structure. Since the inception of this technology in early 2000s, RabMAb primary antibodies have quickly replaced mouse monoclonal antibodies for several important markers such as HER2, c-kit/CD117, estrogen receptor and progesterone receptor in the pathology IHC field. RabMAb primary antibodies improve the effectiveness of certain markers that have been especially difficult in pathology IHC such as ERG, c-myc, bcl-2, MSH-6, MSH2 and PMS2. Because RabMAb primary antibodies offer superior sensitivity and specificity, performance reliability, as well as easy adaption to current automated stainers, it is clear that this group of antibodies is becoming the preferred choice for performing IHC in pathology laboratories.
Rabbit monoclonal antibody developed using a patented and Epitomics’ proprietary rabbit hybridoma technology
This is a preview of subscription content, log in to check access.
Spieker-Polet H, Sethupathi P, Yam PC, Knight KL. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. Proc Natl Acad Sci USA. 1995;92(20):9348–52.CrossRefPubMedCentralPubMedGoogle Scholar
Zhu W, Yu GL. Rabbit hybridoma. In: Andrew Z, editor. Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, NJ: Wiley; 2009. p. 151–68.CrossRefGoogle Scholar
Mage RG, Lanning D, Knight KL. B cell and antibody repertoire development in rabbits: the requirement of gut-associated lymphoid tissues. Dev Comp Immunol. 2006;30(1–2):137–53.CrossRefPubMedGoogle Scholar
Rossi S, Laurino L, Furlanetto A, et al. “Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies. Am J Pathol. 2005;124(2):295–302.Google Scholar
Huang Z, Zhu W, Szekeres G, Xia H. Development of new rabbit monoclonal antibody to estrogen receptor: immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2005;13(1):91–5.CrossRefPubMedGoogle Scholar
Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12(7):590–8.PubMedCentralPubMedGoogle Scholar
Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011;24(7):917–23.CrossRefPubMedGoogle Scholar
Williams AR, Piris J, Wyllie AH. Immunohistochemical demonstration of altered intracellular localization of c-MYC oncogene production in human colorectal neoplasms. J Pathol. 1990;160(4):287–93.CrossRefPubMedGoogle Scholar
Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273–9.CrossRefPubMedCentralPubMedGoogle Scholar